Skip to content
Search

Latest Stories

Arthritis drug baricitinib found effective to treat Covid patients

The NHS on Thursday (May 5) said it has rolled out the arthritis drug baricitinib for seriously ill Covid patients.

The Recovery trial, conducted by the NHS and University of Oxford, found that 13 per cent fewer severely ill patients died of Covid when treated with the drug compared to existing treatment options.


Typically used to treat arthritis to reduce pain and inflammation, baricitinib can now be given to hospitalised Covid patients in addition to current treatments, and clinical studies show that this can provide benefits on top of existing treatment.

The NHS has led the rollout of Covid medicines, from the discovery of dexamethasone as the world’s first effective treatment, to the first vaccination outside of a clinical trial in December 2020.

The NHS said baricitinib works by reducing inflammation caused by Covid-19 by blocking signals to the immune system that are causing it to attack the body.

As well as these arthritis drugs, the NHS continues to use other monoclonal antibody and antiviral treatments, and combined these Covid medicines have been given to hundreds of thousands of patients, saving tens of thousands of lives, the health body added.

"The more effective Covid treatments within the NHS arsenal, the more options doctors have to help patients who become seriously ill with Covid, preventing hospital admissions and saving lives," NHS Medical Director Professor Steve Powis said.

"This is the fourth drug that has been fast-tracked for use on the NHS thanks to the world-leading Recovery trial and is just as important because it gives our hard-working clinicians another life-saving treatment option and strengthens our defence against Covid-19."

The agreement to offer baricitinib to treat Covid patients in hospital follows that of similar drugs, tocilizumab and sarilumab, which are also routinely used for rheumatoid arthritis and other inflammatory conditions.

It will be the seventh Covid treatment approved in total for use on the NHS, and will be used to treat hospitalised patients in line with the MHRA guidance.

Sir Martin Landray, Professor of Medicine and Epidemiology at Oxford Population Health, and Joint Chief Investigator for Recovery, said: "We’re delighted that the Recovery trial has identified another treatment for patients hospitalised with COVID-19.

"Baricitinib works in addition to other proven therapies (such as dexamethasone). Although we have effective vaccines and treatments, hospitalisation with COVID-19 is still associated with poor outcomes so it’s vital that we continue to use randomised trials to identify new therapies that can reduce risk further."

Baricitnib is the fourth treatment that the Recovery trial has shown to save lives, following the steroid dexamethasone, the arthritis treatment tocilizumab, and a combination of monoclonal antibodies (casirivimab plus imdevimab) targeting the viral spike protein, known as Ronapreve.

More For You

Lack of funding deters NI pharmacy contractors from expanding portfolio

W G Hamilton Pharmacy is the third pharmacy in Northern Ireland to be recently sold to first-time buyers.

Pharmacy ownership trends shift in Northern Ireland due to funding gap

An increasing number of pharmacies in Northern Ireland are being acquired by first-time buyers, as existing contractors and groups pull back from expanding their portfolios amid ongoing funding pressures, according to specialist business property adviser Christie & Co.

Among the most recent sales is W G Hamilton Pharmacy, a busy community pharmacy in Ballysillan, North Belfast.

Keep ReadingShow less
RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less